Pyrroloquinoline quinone prevents MK-801-induced stereotypical behavior and cognitive deficits in mice

Behavioural Brain Research

Volumn 258, Issue , 2014, Pages 153-159

  Zhou, Xingqin ^a   Chen, Quancheng ^a   Hu, Xindai ^b   Mao, Shishi ^a   Kong, Yanyan ^a  

^a BEIJING HOSPITAL   (China)

^b EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

Cognitive deficits; MK 801; NMDA receptors; Pyrroloquinoline quinone; Stereotypical

Indexed keywords

DIZOCILPINE; PYRROLOQUINOLINEQUINONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATAXIA; BODY WEIGHT; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; FORCED SWIMMING TEST; LOCOMOTION; MENTAL DISEASE; MOUSE; NEUROPROTECTION; NONHUMAN; OPEN FIELD TEST; PASSIVE AVOIDANCE; PRIORITY JOURNAL; SOCIAL INTERACTION; STEREOTYPY;

COGNITIVE DEFICITS; MK-801; NMDA RECEPTORS; PYRROLOQUINOLINE QUINONE; STEREOTYPICAL;

ANIMALS; BEHAVIOR, ANIMAL; COGNITION; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; NEURONS; PQQ COFACTOR; RECEPTORS, N-METHYL-D-ASPARTATE; SOCIAL BEHAVIOR; STEREOTYPED BEHAVIOR;

EID: 84887200865     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.10.025     Document Type: Article

References (64)

1. Brenner E., Kondziella D., Haberg A., Sonnewald U. Impaired glutamine metabolism in NMDA receptor hypofunction induced by MK801. J Neurochem 2005, 94:1594-1603.
2. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991, 148:1301-1308.
3. Valentina W., Denise M.V. Persistent deficits in hippocampal synaptic plasticity accompany losses of hippocampus-dependent memory in a rodent model of psychosis. Front Integr Neurosci 2013, 7(12). 10.3389/fnint.2013.00012.
4. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994, 51:199-214.
5. Andine P., Axelsson R., Jacobson I. The effect of anosmia on MK-801-induced behaviour in mice. Neurosci Lett 1995, 190:113-116.
6. Collins R.C., Olney J.W. Focal cortical seizures cause distant thalamic lesions. Science 1982, 218:177-179.
7. Sloviter R.S. Epileptic' brain damage in rats induced by sustained electrical stimulation of the perforant path. I. Acute electrophysiological and light microscopic studies. Brain Res Bull 1983, 10:675-697.
8. Gill R., Foster A.C., Woodruff G.N. Systemic administration of MK-801 protects against ischemia-induced hippocampal neurodegeneration in the gerbil. J Neurosci 1987, 7:3343-3349.
9. Kondziella D., Brenner E., Eyjolfsson E.M., Markinhuhta K.R., Carlsson M., Sonnewald U. Glial-neuronal interactions are impaired in the schizophrenia model of repeated MK801 exposure. Neuropsychopharmacology 2006, 31(9):1880-1887.
10. Eyjolfsson E.M., Brenner E., Kondziella D., Sonnewald U. Repeated injection of MK801: an animal model of schizophrenia?. Neurochem Int 2006, 48(6-7):541-546.
11. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988, 1:179-186.
12. Lieberman J.A. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
13. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006, 26:363-382.
14. Thomas R.I. Rethinking schizophrenia. Nature 2010, 468:187-193.
15. de Bartolomeis A., Fiore G., Iasevoli F. Dopamine-Glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis. Curr Pharm Des 2005, 11(27):3561-3594.
16. Abbott A. The drug deadlock. Nature 2010, 468(7321):158-159.
17. Stites T.E., Mitchell A.E., Rucker R.B. Physiological importance of quinoenzymes and the O-quinone family of cofactors. J Nutr 2000, 130:719-727.
18. McIntire W.S. Newly discovered redox cofactors: possible nutritional, medical, and pharmacological relevance to higher animals. Annu Rev Nutr 1998, 18:145-177.
19. Davidson V.L. Pyrroloquinoline quinone (PQQ) from methanol dehydrogenase and tryptophan tryptophylquinone (TTQ) from methylamine dehydrogenase. Adv Protein Chem 2001, 58:95-140.
20. Anthony C. Pyrroloquinoline quinone (PQQ) and quinoprotein enzymes. Antioxid Redox Signaling 2001, 3:757-774.
21. Mitchell A.E., Jones A.D., Mercer R., Rucker R.B. Characterization of pyrroloquinoline quinone amino acid derivatives by electrospray ionization mass spectrometry and detection in human milk. Anal Biochem 1999, 269:317-325.
22. Steinberg F., Stites T., Anderson P., Storms D., Chan I., Eghbali S., Rucker R.B. Pyrroloquinoline quinone improves growth and reproductive performance in mice fed chemically defined diets. Exp Biol Med 2003, 228:160-166.
23. Kasahara T., Kato T. Nutritional biochemistry: a new redox-cofactor vitamin for mammals. Nature 2003, 422:832.
24. Killgore J., Smidt C., Duich L., Romero-Chapman N., Tinker D., Reiser K., Melko M., Hyde D., Rucker R.B. Nutritional importance of pyrroloquinoline quinone. Science 1989, 245:850-852.
25. Yamaguchi K., Sasano A., Urakami T., Tsuji T., Kondo K. Stimulation of nerve growth factor production by pyrroloquinoline quinine and its derivatives in vitro and in vivo. Biosci Biotechnol Biochem 1993, 57:1231-1233.
26. Zhang Y., Rosenberg P.A. The essential nutrient pyrroloquinoline quinine may act as a neunprotectant by suppressing peroxynitrite formation. Eur J Neurosci 2002, 16:1015-1024.
27. Kim J., Harada R., Kobayashi M., Kobayashi N., Sode K. The inhibitory effect of pyrroloquinoline quinine on the amyloid formation and cytotoxicity of truncated alpha-synuclein. Mol Neurodegener 2010, 5:20.
28. Kobayashi M., Kim J., Kobayashi N., Han S., Nakamura C., Ikebukuro K., Sode K. Pyrroloquinoline quinone (PQQ) prevents fibril formation of a-synuclein. Biochem Biophys Res Commun 2006, 349:1139-1144.
29. Ohwada K., Takeda H., Yamazaki M., Isogai H., Nakano M., Shimomura M., Fukui K., Urano S. Pyrroloquinoline quinone (PQQ) prevents cognitive deficit caused by oxidative stress in rats. J Clin Biochem Nutr 2008, 42(1):29-34.
30. Zhou X., Qin X., Cao G., Zhang J., Ion-Pair L.C. Analysis of pyrroloquinoline quinone in neurotransmitter amino acid incubations: determination of chemical kinetics. Chromatographia 2012, 75:521-526.
31. 99mTc-PQQ and preliminary biological evaluation for the NMDA receptor. J Radioanal Nucl Chem 2011, 287:93-101.
32. Wu J., Zou H., Strong J.A., Yu J., Zhou X., Xie Q., Zhao G., Jin M., Yu L. Bimodal effects of MK-801 on locomotion and stereotypy in C57BL/6 mice. Psychopharmacology 2005, 177:256-263.
33. Feinstein I., Kritzer M.F. Acute N-methyl-d-aspartate receptor hypofunction induced by MK-801 evokes sex-specific changes in behaviors observed in open-field testing in adult male and proestrus female rats. Neuroscience 2013, 228:200-214.
34. Sams-Dodd F. Effects of continuous d-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology 1998, 19:18-25.
35. Donnan G.A., Willis G.L., Kaczmarczyk S.J. Motor function in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse. J Neurol Sci 1987, 77(2-3):185-191.
36. Clineschmidt B.V., Martin G.E., Bunting P.R., Papp N.L. Central sympathomimetic activity of (+)-5-methyl-10, 11-dihydro-5H-dibenzo[a,d]cyclobepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic and apparent anxiolytic properties. Drug Dev Res 1982, 2:135-145.
37. Contreras P.C. d-Serine antagonized phencyclidine- and MK-801-induced stereotyped behavior and ataxia. Neuropharmacology 1986, 29:291-293.
38. Criswell H.E., Johnson K.B., Mueller R.A., Breese G.R. Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyI-d-aspartic acid. antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats. J Pharmacol Exp Ther 1993, 265:1001-1010.
39. Koek W., Woods J.H., Winger G.D. MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurutransmission, produces phencyclidine-like behavioral effects in pigeoas, rats and Rhesus monkeys. J Pharmacol Exp Ther 1988, 245:969-974.
40. Sturgeon R.D., Fessler R.G., Meltzer H.Y. Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats. Eur J Pharmacol 1979, 59:169-179.
41. Tiedtke P.I., Bischoff C., Schmidt W.J. MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J Neural Transm Gen Sect 1990, 81:173-182.
42. Murase S., Mathé J.M., Grenhoff J., Svensson T.H. Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: differential actions on firing pattern related to anatomical localization. J Neural Transm Gen Sect 1993, 91:13-25.
43. Hadjiconstantinou M., Rossetti Z.L., Wemlinger T.A., Neff N.H. Dizocilpine enhances striatal tyrosine hydroxylase and aromatic l-amino acid decarboxylase activity. Eur J Pharmacol 1995, 289:97-101.
44. Biggs C.S., Fowler L.J., Whitton P.S., Starr M.S. NMDA receptor antagonists increase the release of dopamine in the substantia nigra of reserpine-treated rats. Eur J Pharmacol 1996, 299:83-91.
45. Mathé J.M., Nomikos G.G., Blakeman K.H., Svensson T.H. Differential actions of dizocilpine (MK-801) on the mesolimbic and mesocortical dopamine systems: role of neuronal activity. Neuropharmacology 1999, 38:121-128.
46. Wolf M.E. Repeated administration of MK-801 produces sensitization to its own locomotor stimulant effects but blocks sensitization to amphetamine. Brain Res 1991, 562:164-168.
47. Xu X. Phencyclidine-induced behavioral sensitization. Pharmacol Biochem Behav 1994, 47:603-608.
48. Cook C.D., Newman J.L., Winfree J.C., Beardsley P.M. Modulation of the locomotor activating effects of the noncompetitive NMDA receptor antagonist MK801 by dopamine D2/3 receptor agonists in mice. Pharmacol Biochem Behav 2004, 77:309-318.
49. Kalinichev M., Robbins M.J., Hartfield E.M., Maycox P.R., Moore S.H., Savage K.M. Comparison between intraperitoneal and subcutaneous phencyclidine administration in Sprague-Dawley rats: a locomotor activity and gene induction study. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:414-422.
50. Jentsch J.D. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine (see comments). Science 1997, 277:953-955.
51. Jentsch J.D., Tran A., Jentsch J.D., Le D., Youngren K.D., Roth R.H. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 1997, 17:92-99.
52. Hoehn-Saric R., McLeod D.R., Glowa J.R. The effects of NMDA receptor blockade on the acquisition of a conditioned emotional response. Biol Psychiatry 1991, 30(2):170-176.
53. Sams-Dodd F. Automation of the social interaction test by a video-tracking system: behavioural effects of repeated phencyclidine treatment. J Neurosci Methods 1995, 59(2):157-167.
54. Schulz B., Fendt M., Pedersen V., Koch M. Sensitization of prepulse inhibition deficits by repeated administration of dizocilpine. Psychopharmacology (Berlin) 2001, 156(2-3):177-181.
55. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999, 20:201-225.
56. Bubeníková V., Votava M., Horácek J., Pálenícek T., Dockery C. The effect of zotepine, risperidone, clozapine and olanzapine on MK-801-disrupted sensorimotor gating. Pharmacol Biochem Behav 2005, 80:591-596.
57. Aizerman E., Hartriett K.A., Zhong C., Gallop P.M., Rosenberg P.A. Interaction of the putative essential nutrient pyrroloquinoline quinine with the N-methyl-d-aspartate receptor redox modulatory site. J Neurosci 1992, 12:2362-2369.
58. Porat Y., Abramowitz A., Gazit E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 2006, 67:27-37.
59. Zhang Y., Feustel P.J., Kimelberg H.K. Neuroprotection by pyrroloquinoline quinone (PQQ) in reversible middle cerebral artery occlusion in the adult rat. Brain Res 2006, 1094:200-206.
60. Rucker R., Chowanadisai W., Nakano M. Potential physiological importance of pyrroloquinoline quinine. J Altern Med Rev 2009, 14:268-277.
61. Naito Y., Kumazawa T., Kino L., Suzuki O. Effects of pyrroloquinoline quinone (PQQ) and PQQ-oxazole on DNA synthesis of cultured human fibroblasts. Life Sci 1993, 52:1909-1915.
62. Kocerha J., Faghihi M.A., Lopez-Toledano M.A., Huang J., Ramsey A.J., Caron M.G., Sales N., Willoughby D., Elmen J., Hansen H.F., Orum H., Kauppinen S., Kenny P.J., Wahlestedt C. MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. PNAS 2009, 106(9):3507-3512.
63. Gong D., Geng C., Jiang L., Aoki Y., Nakano M., Zhong L. Effect of pyrroloquinoline quinone on neuropathic pain following chronic constriction injury of the sciatic nerve in rats. Eur J Pharmacol 2012, 697(1-3):53-58.
64. Snyder S.H., Ferris C.D. Novel neurotransmitters and their neuropsychiatric relevance. Am J Psychiatry 2000, 157:1738-1751.